Aliases & Classifications for Hemarthrosis

MalaCards integrated aliases for Hemarthrosis:

Name: Hemarthrosis 12 51 41 14 69
Hemarthrosis Involving Pelvic Region and Thigh 12
Haemarthrosis of the Pelvic Region and Thigh 12
Hemarthrosis of the Pelvic Region and Thigh 12
Hemarthrosis Involving Shoulder Region 12
Hemarthrosis Involving Ankle and Foot 12
Hemarthrosis of the Ankle and/or Foot 12
Haemarthrosis of the Ankle and Foot 12
Hemarthrosis of the Shoulder Region 12
Hemarthrosis of the Ankle and Foot 12
Hemarthrosis of Ankle and/or Foot 12
Hemarthrosis Involving Lower Leg 12
Hemarthrosis Involving Upper Arm 12
Haemarthrosis of Shoulder Joint 12
Hemarthrosis of Shoulder Region 12
Hemarthrosis Involving Forearm 12
Hemarthrosis of the Lower Leg 12
Hemarthrosis of the Upper Arm 12
Hemarthrosis Involving Hand 12
Hemarthrosis of the Forearm 12
Hemarthrosis of Lower Leg 12
Hemarthrosis of Upper Arm 12
Hemarthrosis of Shoulder 12
Hemarthrosis of the Hand 12
Hemarthrosis of Forearm 12
Hemarthrosis of Hand 12

Classifications:



External Ids:

Disease Ontology 12 DOID:801
ICD10 32 M25.0
ICD9CM 34 719.1 719.10
MeSH 41 D006395
UMLS 69 C0018924

Summaries for Hemarthrosis

MalaCards based summary : Hemarthrosis, also known as hemarthrosis involving pelvic region and thigh, is related to factor v deficiency and factor x deficiency, and has symptoms including stiffness of joint, not elsewhere classified in icd10cm, other symptoms referable to joint and metatarsalgia. An important gene associated with Hemarthrosis is F8 (Coagulation Factor VIII), and among its related pathways/superpathways are Metabolism of proteins and Response to elevated platelet cytosolic Ca2+. The drugs Bevacizumab and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, b cells and monocytes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 72 Hemarthrosis (or haemarthrosis) is a bleeding into joint spaces. It is a common feature of... more...

Related Diseases for Hemarthrosis

Diseases related to Hemarthrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
# Related Disease Score Top Affiliating Genes
1 factor v deficiency 31.1 F7 F8 F9
2 factor x deficiency 31.1 F10 F7 F9 VWF
3 afibrinogenemia, congenital 31.0 F8 VWF
4 factor vii deficiency 30.8 F10 F7 F8 F9
5 factor xi deficiency 29.9 F8 F9
6 acquired hemophilia 29.7 F10 F8 F9
7 vitamin k deficiency hemorrhagic disease 29.6 BGLAP F8
8 hemophilia 29.3 F7 F8 F9 VWF
9 arthropathy 29.3 F8 F9
10 glanzmann thrombasthenia 29.2 F8 F9 VWF
11 von willebrand's disease 28.9 F8 F9 VWF
12 hemophilia b 28.9 F10 F7 F8 F9
13 myocardial infarction 28.8 F10 F7 F8 VWF
14 hemophilia a 28.3 F10 F7 F8 F9 VWF
15 hemorrhagic disease 28.0 F10 F7 F8 F9 VWF
16 severe hemophilia b 10.2 F8 F9
17 acquired hemophilia a 10.2 F8 F9
18 cardiac tamponade 10.2 F8 F9
19 x-linked disease 10.1 F8 F9
20 synovitis 10.1
21 malignant skin fibrous histiocytoma 10.1 F7 F9
22 malignant dermis tumor 10.1 F7 F9
23 pulmonary embolism 10.1 F10 F9
24 arthritis 10.0
25 papillary cystadenocarcinoma 10.0 BGLAP SPP1
26 hypophosphatasia, adult 10.0 BGLAP SPP1
27 adamantinoma of long bones 10.0 BGLAP SPP1
28 fainting 10.0 F8 VWF
29 von willebrand disease, type 3 10.0 F8 VWF
30 cerebral arteritis 9.9 F8 VWF
31 von willebrand disease, type 1 9.9 F8 VWF
32 osteofibrous dysplasia 9.9 BGLAP SPP1
33 factor viii deficiency 9.9 F8 VWF
34 carotid stenosis 9.9 F7 SPP1
35 bone resorption disease 9.9 BGLAP SPP1
36 intracranial thrombosis 9.9 F8 VWF
37 acute myocardial infarction 9.9
38 thrombasthenia 9.9
39 aneurysm 9.9
40 lymphangiosarcoma 9.9 F8 VWF
41 prothrombin deficiency 9.9 F7 F8 F9
42 lipomatosis, multiple 9.8
43 osteoarthritis with mild chondrodysplasia 9.8
44 osteoarthritis 9.8
45 pigmented villonodular synovitis 9.8
46 purpura 9.8
47 villonodular synovitis 9.8
48 aortic valve disease 1 9.7 SPP1 VWF
49 mild hemophilia a 9.7 F10 F8 VWF
50 afibrinogenemia 9.7 F10 F8 VWF

Graphical network of the top 20 diseases related to Hemarthrosis:



Diseases related to Hemarthrosis

Symptoms & Phenotypes for Hemarthrosis

UMLS symptoms related to Hemarthrosis:


stiffness of joint, not elsewhere classified in icd10cm, other symptoms referable to joint, metatarsalgia, hemoptysis, arthralgia

MGI Mouse Phenotypes related to Hemarthrosis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.35 F9 SPP1 VWF F10 F7
2 homeostasis/metabolism MP:0005376 9.1 F8 F9 SPP1 VWF F10 F7

Drugs & Therapeutics for Hemarthrosis

Drugs for Hemarthrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
4
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
5
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
6
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
7
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
8 Racepinephrine Approved Phase 4 329-65-7
9 tannic acid Approved, Nutraceutical Phase 4,Phase 3
10 Coagulants Phase 4,Phase 3,Phase 2
11 Angiogenesis Inhibitors Phase 4
12 Angiogenesis Modulating Agents Phase 4
13 Factor VIII Phase 4,Phase 3,Phase 2
14 triamcinolone acetonide Phase 4
15 Adjuvants, Immunologic Phase 4
16 Triamcinolone diacetate Phase 4
17 Triamcinolone hexacetonide Phase 4
18 Viscosupplements Phase 4
19 Hylan Phase 4
20 Protective Agents Phase 4
21 Analgesics Phase 4
22 Respiratory System Agents Phase 4
23 Central Nervous System Depressants Phase 4
24 Adrenergic Agents Phase 4
25 Adrenergic Agonists Phase 4
26 Adrenergic alpha-Agonists Phase 4
27 Mydriatics Phase 4
28 Adrenergic beta-Agonists Phase 4
29 Narcotics Phase 4
30 Neurotransmitter Agents Phase 4
31 Vasoconstrictor Agents Phase 4
32 Anesthetics Phase 4
33 Anesthetics, Local Phase 4
34 Peripheral Nervous System Agents Phase 4
35 Anti-Asthmatic Agents Phase 4
36 Epinephryl borate Phase 4
37 Autonomic Agents Phase 4
38 Bronchodilator Agents Phase 4
39
Thrombin Approved, Investigational Phase 3
40 Immunoglobulin Fc Fragments Phase 3
41 Immunoglobulins Phase 3
42 Antibodies Phase 3
43 Antibodies, Bispecific Phase 3
44 Hemostatics Phase 2
45
Chlorhexidine Approved, Vet_approved 55-56-1 2713 9552079
46
Povidone-iodine Approved 25655-41-8
47 Chlorhexidine gluconate
48 Soy Bean Nutraceutical

Interventional clinical trials:

(show top 50) (show all 78)

# Name Status NCT ID Phase Drugs
1 Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis Unknown status NCT02060305 Phase 4 Bevacizumab intra-articular injection
2 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
3 Trial of NovoSeven® in Haemophilia - Joint Bleeds Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
4 High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors Completed NCT00571584 Phase 4 activated recombinant human factor VII
5 Viscosupplementation in Patients With Hemophilic Arthropathy Completed NCT01748201 Phase 4
6 Russian Kogenate Pediatric Study Completed NCT00632814 Phase 4 rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week;rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg);rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
7 BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Completed NCT00586521 Phase 4 Kogenate (BAY14-2222)
8 Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy Completed NCT00638001 Phase 4
9 Canadian Hemophilia Prophylaxis Study Completed NCT01085344 Phase 4
10 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A Completed NCT01810666 Phase 4
11 Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens Completed NCT00927667 Phase 4
12 Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A Completed NCT02697370 Phase 4 Pharmacokinetic based dosage change
13 Effect of Local Anesthetic Injection and Hemarthrosis Aspiration on Pain and Narcotic/Opioid Analgesia Use-Tibial Plateau Fractures Recruiting NCT02951884 Phase 4 Bupivacaine with Epinephrine
14 A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children Recruiting NCT02999308 Phase 4
15 Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B Completed NCT00364182 Phase 3 Recombinant Coagulation Factor IX (BeneFIX);Recombinant Coagulation Factor IX (BeneFIX)
16 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A Completed NCT01458106 Phase 3 BIIB031 (rFVIIIFc);FVIII (PK subgroup only)
17 Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B Completed NCT01440946 Phase 3 rFIXFc;FIX
18 Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A Completed NCT01454739 Phase 3 rFVIIIFc
19 Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B Completed NCT01425723 Phase 3
20 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A Completed NCT01181128 Phase 3 Factor VIII (rFVIIIFc);Advate®
21 Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B Recruiting NCT02234310 Phase 3
22 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors Recruiting NCT03417245 Phase 3 fitusiran;factor VIII or factor IX
23 A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors Recruiting NCT03417102 Phase 3 fitusiran;recombinant Factor VIIa and FEIBA
24 An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A Recruiting NCT02234323 Phase 3
25 A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors Active, not recruiting NCT02795767 Phase 3 Emicizumab
26 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors Active, not recruiting NCT02622321 Phase 3 Emicizumab;rFVIIa;aPCC
27 A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Active, not recruiting NCT02847637 Phase 3 Emicizumab
28 BAX 855 PK-Guided Dosing Active, not recruiting NCT02585960 Phase 3
29 A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A Active, not recruiting NCT01580293 Phase 2, Phase 3
30 Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants Not yet recruiting NCT03315455 Phase 3 Emicizumab
31 Early Prophylaxis Immunologic Challenge (EPIC) Study Terminated NCT01376700 Phase 3
32 rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors Unknown status NCT01105546 Phase 2 recombinant activated factor VII;recombinant activated factor VII
33 Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds Completed NCT00486278 Phase 2 eptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated);vatreptacog alfa (activated)
34 Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII Completed NCT00245245 Phase 2 recombinant porcine coagulation factor VIII (OBI-1)
35 A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy Recruiting NCT02994147 Phase 2 Placebo;AC-201CR
36 BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A Terminated NCT00623727 Phase 2
37 Individualized Prophylaxis for Severe Hemophilia A Children Unknown status NCT02116855
38 The Effect of Functional Activities and Balance Ability With Taping in Subjects of Hemophilia Unknown status NCT02389205
39 Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait. Unknown status NCT02229331
40 Musculoskeletal Function in Hemophilia Unknown status NCT00324493
41 Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia Unknown status NCT02165592
42 Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors Completed NCT01234545 activated recombinant human factor VII
43 Efficacy of Peroperative Suction Drain Usage in Arthroscopic Knee Surgery Completed NCT02752581
44 The FEIBA NovoSeven Comparative Study Completed NCT00166309 FEIBA and NovoSeven
45 Physiotherapy in the Haemophilic Arthropathy of the Elbow. Completed NCT02198040
46 Manual Therapy in Haemophilic Arthropathy of the Knee Completed NCT02198014
47 The Von Willebrand Disease (VWD) International Prophylaxis Study Completed NCT00557908 VWF/FVIII products
48 Multidisciplinary Evaluation of Patients With Hemophilia Completed NCT02198430
49 Gait Evaluation in Haemophiliac Patients Completed NCT00824798
50 Educational Physiotherapy in Haemophilia Completed NCT02825706

Search NIH Clinical Center for Hemarthrosis

Cochrane evidence based reviews: hemarthrosis

Genetic Tests for Hemarthrosis

Anatomical Context for Hemarthrosis

MalaCards organs/tissues related to Hemarthrosis:

38
Bone, B Cells, Monocytes, Myeloid, Skeletal Muscle

Publications for Hemarthrosis

Articles related to Hemarthrosis:

(show top 50) (show all 232)
# Title Authors Year
1
Embolization of the Geniculate Arteries Is an Effective Treatment of Recurrent Hemarthrosis Following Total Knee Arthroplasty That Can Be Safely Repeated. ( 29224993 )
2017
2
Hemarthrosis and scurvy. ( 28433625 )
2017
3
Recurrent Hemarthrosis due to Iatrogenic AVF Treated With Onyx Embolization. ( 28446073 )
2017
4
Spontaneous elbow hemarthrosis identified by point-of-care ultrasound. ( 28435904 )
2017
5
Hemarthrosis subtalar, a rare diagnosis. ( 28409144 )
2017
6
Endovascular Management of Recurrent Spontaneous Hemarthrosis After Arthroplasty. ( 27882429 )
2017
7
Acute hemophilic hemarthrosis: is local cryotherapy recommended? ( 29020808 )
2017
8
Capsulotomy as a measure to control pain and reducing hemarthrosis in arthroscopic DB ACL reconstruction surgery: a prospective randomized control study. ( 29086025 )
2017
9
Spontaneous Hemarthrosis of the Knee - Late Complication of Flexible Femur Nailing: A Case Report. ( 28180118 )
2016
10
Acute Hemarthrosis of the Knee Caused by Arteriovenous Malformation. ( 27231206 )
2016
11
Technically Successful Geniculate Artery Embolization Does Not Equate Clinical Success for Treatment of Recurrent Knee Hemarthrosis after Knee Surgery. ( 26806692 )
2016
12
Spontaneous Recurrent Hemarthrosis of the Knee: A Report of Two Cases with a Source of Bleeding Detected during Arthroscopic Surgery of the Knee Joint. ( 27703824 )
2016
13
Effects of hemarthrosis on cartilage and synovium in rabbits. ( 26936196 )
2016
14
Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis. ( 28039188 )
2016
15
Reducing Intra-articular Hemarthrosis After Arthroscopic ACL Reconstruction: Response. ( 26929179 )
2016
16
Reducing Intra-articular Hemarthrosis After Arthroscopic ACL Reconstruction: Letter to the Editor. ( 26929178 )
2016
17
Geniculate Artery Embolization for Management of Recurrent Hemarthrosis: A Single-Center Experience. ( 27338503 )
2016
18
Epidemiology of intra- and peri-articular structural injuries in traumatic knee joint hemarthrosis - data from 1145 consecutive knees with subacute MRI. ( 27374877 )
2016
19
Geniculate artery embolization for recurrent postarthroplasty hemarthrosis of the knee. ( 27398122 )
2015
20
Joint Aspiration for Acute Hemarthrosis in Children Receiving Factor VIII Prophylaxis for Severe Hemophilia: 11-year Safety Data. ( 25729030 )
2015
21
LASER versus electromagnetic field in treatment of hemarthrosis in children with hemophilia. ( 26306883 )
2015
22
Recurrent Hemarthrosis Following Knee Arthroplasty Treated with Arterial Embolization. ( 26092252 )
2015
23
Reducing Intra-articular Hemarthrosis After Arthroscopic Anterior Cruciate Ligament Reconstruction by the Administration of Intravenous Tranexamic Acid: A Prospective, Randomized Controlled Trial. ( 26337246 )
2015
24
Spontaneous hemarthrosis following fibrinolytic therapy for acute myocardial infarction: a case report and literature review. ( 25417208 )
2014
25
Occult Intra-articular Knee Injuries in Children With Hemarthrosis. ( 24753236 )
2014
26
Spontaneous hemarthrosis in combined Glanzmann thrombasthenia and type 2N von Willebrand disease. ( 24418945 )
2014
27
Anticoagulant-induced hemarthrosis presenting as anterior shoulder dislocation. ( 25043625 )
2014
28
Selective arterial embolization with gelatin particles for refractory knee hemarthrosis. ( 23846552 )
2013
29
Recurrent hemarthrosis after total knee arthroplasty caused by the impingement of a remnant lateral meniscus: A case report. ( 24231622 )
2013
30
Hemophilic chronic synovitis: therapy of hemarthrosis using endovascular embolization of knee and elbow arteries. ( 23150120 )
2013
31
Geniculate artery embolization in the management of spontaneous recurrent hemarthrosis of the knee: case series. ( 23433418 )
2013
32
A case of selective arterial embolization for recurrent hemarthrosis after total knee arthroplasty. ( 22237971 )
2013
33
Hemarthrosis in hemophilic mice results in alterations in M1-M2 monocyte/macrophage polarization. ( 24252538 )
2013
34
A case of bilateral hemarthrosis due to pseudoaneurysms in a patient on anticoagulation therapy. ( 23669803 )
2013
35
Recurrent hemarthrosis : an unusual cause. ( 23680622 )
2013
36
Antiplasmin, but not amiloride, prevents synovitis and cartilage damage following hemarthrosis in hemophilic mice. ( 24283895 )
2013
37
Transarterial embolization for the management of hemarthrosis of the knee. ( 22154590 )
2012
38
MRI findings in adolescent patients with acute traumatic knee hemarthrosis. ( 23147616 )
2012
39
Spontaneous recurrent hemarthrosis of the knee joint in the elderly: a report of two cases. ( 21607723 )
2012
40
Hemarthrosis in a patient on warfarin receiving ceftaroline: a case report and brief review of cephalosporin interactions with warfarin. ( 22764328 )
2012
41
Cartilage and bone markers and inflammatory cytokines are increased in synovial fluid in the acute phase of knee injury (hemarthrosis)--a cross-sectional analysis. ( 22874525 )
2012
42
Knee hemarthrosis after arthroscopic surgery in an athlete with low factor XIII activity. ( 23031577 )
2012
43
Intra-articular nodular fasciitis of the knee: a rare cause of recurrent hemarthrosis. ( 21431289 )
2012
44
Magnetic resonance angiography in the management of recurrent hemarthrosis after total knee arthroplasty. ( 21397454 )
2011
45
Does the source of hemarthrosis influence posttraumatic joint contracture and biomechanical properties of the joint? ( 21420211 )
2011
46
Recurrent hemarthrosis after unicompartmental knee arthroplasty. ( 21902161 )
2011
47
Trauma resulting in hemarthrosis and long medial collateral ligament desmitis of the tarsocrural joint in a horse. ( 22043073 )
2011
48
A rare case of meniscal hematoma with hemarthrosis of the knee: a case report. ( 21938355 )
2011
49
Recurrent hemarthrosis in a boy with synovial hemangioma: a case report. ( 21088622 )
2011
50
Recurrent hemarthrosis in a hemophilic patient after revision total knee arthroplasty. ( 20954656 )
2010

Variations for Hemarthrosis

Expression for Hemarthrosis

Search GEO for disease gene expression data for Hemarthrosis.

Pathways for Hemarthrosis

Pathways related to Hemarthrosis according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 BGLAP F10 F7 F8 F9
2
Show member pathways
12.8 F10 F7 F8 F9 VWF
3
Show member pathways
12.39 F10 F7 F8 F9
4
Show member pathways
11.76 F10 F7 F8 F9 VWF
5
Show member pathways
11.59 BGLAP F10 F7 F9
6 11.5 F10 F7 F8 F9 VWF
7 11.48 BGLAP SPP1
8 11.13 BGLAP SPP1
9 11.09 BGLAP SPP1
10 11 BGLAP SPP1
11 10.1 BGLAP F10 F7 F9

GO Terms for Hemarthrosis

Cellular components related to Hemarthrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.72 BGLAP F7 F8 F9 SPP1
2 extracellular region GO:0005576 9.7 BGLAP F10 F7 F8 F9 SPP1
3 vesicle GO:0031982 9.43 BGLAP F7 SPP1
4 platelet alpha granule lumen GO:0031093 9.37 F8 VWF
5 Golgi lumen GO:0005796 9.26 BGLAP F10 F7 F9
6 endoplasmic reticulum lumen GO:0005788 9.1 BGLAP F10 F7 F8 F9 SPP1

Biological processes related to Hemarthrosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.8 F10 F7 F8 F9 VWF
2 ER to Golgi vesicle-mediated transport GO:0006888 9.77 BGLAP F10 F7 F8 F9
3 signal peptide processing GO:0006465 9.56 BGLAP F10 F7 F9
4 response to estrogen GO:0043627 9.51 BGLAP F7
5 blood coagulation, extrinsic pathway GO:0007598 9.5 F10 F7 F9
6 response to nutrient levels GO:0031667 9.49 BGLAP F7
7 biomineral tissue development GO:0031214 9.48 BGLAP SPP1
8 response to vitamin D GO:0033280 9.46 BGLAP SPP1
9 blood coagulation, intrinsic pathway GO:0007597 9.46 F10 F8 F9 VWF
10 response to vitamin K GO:0032571 9.43 BGLAP F7
11 peptidyl-glutamic acid carboxylation GO:0017187 9.26 BGLAP F10 F7 F9
12 hemostasis GO:0007599 9.02 F10 F7 F8 F9 VWF

Molecular functions related to Hemarthrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.33 F10 F7 F9
2 endopeptidase activity GO:0004175 9.26 F7 F9
3 calcium ion binding GO:0005509 9.26 BGLAP F10 F7 F9
4 serine-type peptidase activity GO:0008236 8.8 F10 F7 F9

Sources for Hemarthrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....